ZYBERNO
Stock Report
Updated Aug 28, 2026

Alcon Inc. (ALC)

Healthcare • NYSE

$72.23
Alcon Inc. is a Swiss-American multinational pharmaceutical company headquartered in Geneva, Switzerland, specializing in eye care products. Spun off from Novartis in 2019, Alcon is the world's largest eye care device company, operating through two segments: Surgical (intraocular lenses, surgical equipment, and consumables) and Vision Care (contact lenses and eye care products), serving eye care professionals and patients in over 140 countries.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
40.0/100
WEAK BUSINESS
Alcon Inc. (ALC) scores 40/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
Margin of Safety unavailable — insufficient data for the owner-earnings DCF.
Is the market underestimating or overestimating what this business is capable of going forward?
-13.5%
Market Overestimates
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.19x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (4.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Alcon Inc. (ALC) stock report — Zyberno Score 40/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

According to Zyberno's DCF model, Alcon Inc. (ALC) shows a Brina Gap of -13.5%, which weakens the case: based on the company's ROIC (4.1%) and reinvestment rate (53.2%), the business can fundamentally grow at 2.2% — but the current enterprise value implies the market expects 15.7%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:72.23
Market Cap:$35.21B

Valuation Multiples (2)

P/B Ratio:1.60x
Peg Ratio:-999.00x

Enterprise Metrics (3)

Enterprise Value:$37.84B
Ev Ebitda Ratio:27.82x
Pfcf Ratio:20.37x

Price Action & Momentum (3)

Momentum Percentile:20 / 100
% of 52-Week High:105.7%
B. Profitability Assessment

Return Metrics (5)

Reinvestment Rate:53.2%
Fundamental Growth Rate (g):2.2%
Market-Implied Growth Rate:15.7%

Margin Analysis (1)

Ebitda Margin:13.1%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.5%
C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):9.4%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):7.4%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):6.3%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.12x
Quick Ratio:1.33x
Cash Ratio:0.50x

Leverage Analysis (3)

Debt To Equity Ttm:0.19x
Debt-to-Equity Ratio:0.19x
Debt To Ebitda:3.06x

Coverage Ratios (2)

Interest Coverage Ratio:7.56x
Times Interest Earned:7.56

Capital Structure (4)

Working Capital:3,400,000,000.00
Cash And Cash Equivalents:1,527,000,000.00
Long Term Debt:$4.16B
Net Debt:$2.64B
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $10.40B
Linear Growth: 9.4%
📊 Click to view full ALC Revenue analysis & methodology →
Cost Of Revenue Ttm:$4.59B

Profitability Breakdown (2)

Gross profit TTM: $5.81B
Linear Growth: 14.9%
📊 Click to view full ALC Gross Profit analysis & methodology →
Operating income TTM: $1.36B
Linear Growth: 6.3%
📊 Click to view full ALC Operating Income analysis & methodology →

Bottom Line Performance (3)

Net income TTM: $980.00M
Linear Growth: 7.4%
📊 Click to view full ALC Net Income analysis & methodology →
Income Before Tax:$0.00
Ebitda Ttm:1,360,000,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$123.00M
Interest Expense:180,000,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:13.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$31.56B
Current Assets:$6.45B
Ppe Net:4,774,000,000.00
Goodwill:9,256,000,000.00
Intangible Assets:$9.01B

Liability Structure (4)

Total Liabilities:9,520,000,000.00
Current Liabilities:3,049,000,000.00
Long Term Debt:$4.16B
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$22.04B
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:2,391,000,000.00
Accounts Payable:926,000,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

$2.27B$1.73B

Investment Activities (1)

Investing Cash Flow:-$1.34B

Financing Activities (3)

Financing Cash Flow:-$1.12B
Dividends Paid Ttm:166,000,000.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:$2.01

Revenue & Cash Per Share (2)

Sales Per Share Ttm:21.34
Operating Cash Flow Per Share:$4.66

Book Value & Capital (2)

Book Value Per Share:$45.21
Cash Per Share:3.13

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.33x
Working Capital Turnover Ttm:3.06x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:1.92x
Days Inventory Outstanding Ttm:190.05

Payables & Cash Cycle (2)

Days Payable Outstanding:73.60
Cash Conversion Cycle:-882.55
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:100.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (4)

Reinvestment Rate:53.2%
Fundamental Growth Rate (g):2.2%
Market-Implied Growth Rate:15.7%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (3)

Revenue Growth Rate (Linear):9.4%
Net Income Growth Rate (Linear):7.4%
Operating Income Growth Rate (Linear):6.3%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):14.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:ALC
Company Name:Alcon Inc.
Sector:Healthcare
Industry:Ophthalmic Goods
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:487.43M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-28 18:53:58 UTC
Data Timestamp:2026-08-28T18:53:58.933580
Scroll to Top